Fernández-Reyes M J, Bajo M A, del Peso G, Olea T, Sánchez-Villanueva R L, González E, Heras M, Sánchez R, Selgas R
Servicio de Nefrología, Hospital General de Segovia, Segovia, Spain.
Nefrologia. 2009;29(2):130-5. doi: 10.3265/Nefrologia.2009.29.2.4994.en.full.
Peritoneal permeability differs between patients at the time of starting peritoneal dialysis (PD) and it can increase along with time on the technique. This fact is related to peritonitis, the biocompatibility of the dialysis fluids and the use of glucose as osmotic agent. The aim of the present study was to evaluate if the use of one exchange a day of icodextrine from the time of DP initiation affects the evolution of peritoneal permeability.
56 patients starting PD (mean age: 48.3 +/- 14.0; 62.5% males; 17.9% diabetics) that used one exchange a day with icodextrine from the time of starting PD. We performed a peritoneal transport kinetic study at the time of starting PD and then every 6 months during two years. We calculated the peritoneal mass transfer area coefficient of creatinine (Cr-MTAC) and urea (U-MTAC) as well as the D/P creatinine relationship (D/P Cr). As a control group we used the results of Cr-MTC of 249 patients that had used glucose as the only osmotic agent from the time of starting PD.
The peritoneal transport, calculated using Cr-MTC, U-MTC and D/P Cr, diminished at 12 months (11.7+/-5.7 vs. 8.1+/-3.1; 23.5+/-7.3 vs. 18.9+/-3.8; 0.72+/-0.09 vs. 0.67+/-0.08; respectively), staying stable afterwards.We found that high transporters (HA) patients (higher quatril Cr-MTC ) showed a higher diminution of Cr-MTAC along the first year of treatment. The diminution of Cr-MTAC after 12 months using icodextrine was significantly higher (p<0.001) that the one observed in the control group that only used glucose as osmotic agent (10.5+/-5.3 vs. 10.1+/-4.6). We found that high transporters (HA) patients (higher quatril Cr-MTC) showed a higher decrease of Cr-MTAC along the first year of treatment.
the use of icodextrine at the time of starting PD might help to correct the high transport status observed in some patients during the first months of treatment. The peritoneal transport kinetic studies performed at 6 and 12 months after starting PD are more representative of the long term peritoneal transport characteristics of the patients than those performed at the time of starting PD.
开始腹膜透析(PD)时患者的腹膜通透性存在差异,且随着透析技术使用时间的延长可能会增加。这一事实与腹膜炎、透析液的生物相容性以及使用葡萄糖作为渗透剂有关。本研究的目的是评估从开始腹膜透析时起每天进行一次艾考糊精交换是否会影响腹膜通透性的变化。
56例开始腹膜透析的患者(平均年龄:48.3±14.0岁;男性占62.5%;糖尿病患者占17.9%),从开始腹膜透析时起每天进行一次艾考糊精交换。在开始腹膜透析时以及随后的两年中每6个月进行一次腹膜转运动力学研究。我们计算了肌酐(Cr-MTAC)和尿素(U-MTAC)的腹膜质量转移面积系数以及D/P肌酐比值(D/P Cr)。作为对照组,我们使用了249例从开始腹膜透析时起仅使用葡萄糖作为渗透剂的患者的Cr-MTC结果。
使用Cr-MTC、U-MTC和D/P Cr计算的腹膜转运在12个月时降低(分别为11.7±5.7对8.1±3.1;23.5±7.3对18.9±3.8;0.72±0.09对0.67±0.08),此后保持稳定。我们发现高转运者(HA)患者(四分位Cr-MTC较高)在治疗的第一年中Cr-MTAC的降低幅度更大。使用艾考糊精12个月后Cr-MTAC的降低幅度显著高于(p<0.001)仅使用葡萄糖作为渗透剂的对照组(10.5±5.3对10.1±4.6)。我们发现高转运者(HA)患者(四分位Cr-MTC较高)在治疗的第一年中Cr-MTAC的降低幅度更大。
开始腹膜透析时使用艾考糊精可能有助于纠正一些患者在治疗最初几个月中观察到的高转运状态。在开始腹膜透析后6个月和12个月进行的腹膜转运动力学研究比开始腹膜透析时进行的研究更能代表患者的长期腹膜转运特征。